Cancer Vaccine Kills and Prevents Brain Cancer

Topic: CRISPR
Author: Brigham and Women's Hospital
Published: 2023/01/06 - Updated: 2023/06/28
Publication Type: Medical Research - Peer-Reviewed: Yes
Contents: Summary - Introduction - Main Item - Related Topics

Synopsis: Engineering living tumor cells using the gene-editing tool CRISPR-Cas9 and repurposing them to release tumor cell-killing agent. Like homing pigeons returning to roost, living tumor cells will travel long distances across the brain to return to the site of their fellow tumor cells. Taking advantage of this unique property, researchers engineered living tumor cells using the gene-editing tool CRISPR-Cas9 and repurposed them to release tumor cell-killing agents.

Introduction

Bifunctional Cancer Cell-Based Vaccine Concomitantly Drives Direct Tumor Killing and Antitumor Immunity - Science Translational Medicine.

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, Ph.D., at Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, investigators have developed a new cell therapy approach to eliminate established tumors and induce long-term immunity, training the immune system so that it can prevent cancer from recurring. With promising results, the team tested their dual-action, cancer-killing vaccine in an advanced mouse model of the deadly brain cancer, glioblastoma. Findings are published in Science Translational Medicine.

Main Item

"Our team has pursued a simple idea: to take cancer cells and transform them into cancer killers and vaccines," said corresponding author Khalid Shah, MS, Ph.D., director of the Center for Stem Cell and Translational Immunotherapy (CSTI) and the vice chair of research in the Department of Neurosurgery at the Brigham and faculty at Harvard Medical School and Harvard Stem Cell Institute (HSCI). "Using gene engineering, we are repurposing cancer cells to develop a therapeutic that kills tumor cells and stimulates the immune system to destroy primary tumors and prevent cancer."

Cancer vaccines are an active area of research for many labs, but Shah and his colleagues' approach is distinct. Instead of using inactivated tumor cells, the team repurposes living tumor cells, which possess an unusual feature. Like homing pigeons returning to roost, living tumor cells will travel long distances across the brain to return to the site of their fellow tumor cells. Taking advantage of this unique property, Shah's team engineered living tumor cells using the gene-editing tool CRISPR-Cas9 and repurposed them to release tumor cell killing agent.

In addition, the engineered tumor cells were designed to express factors that would make them easy for the immune system to spot, tag, and remember, priming the immune system for a long-term anti-tumor response.

The team tested their repurposed CRISPR-enhanced and reverse-engineered therapeutic tumor cells (ThTC) in different mice strains, including the one that bore bone marrow, liver, and thymus cells derived from humans, mimicking the human immune microenvironment.

Continued below image.
Scientists developed a bifunctional therapeutic strategy by transforming living tumor cells into a therapeutic. Shah's team engineered living tumor cells using the gene-editing tool CRISPR-Cas9 and repurposed them to release tumor cell-killing agents. In addition, the engineered tumor cells were designed to express factors that would make them easy for the immune system to spot, tag, and remember, priming the immune system for a long-term anti-tumor response. The team tested their repurposed CRISPR-enhanced and reverse-engineered therapeutic tumor cells (ThTC) in different mice strains, including the one that bore bone marrow, liver, and thymus cells derived from humans, mimicking the human immune microenvironment. Shah's team also built a two-layered safety switch into the cancer cell, which, when activated, eradicates ThTCs if needed - Image Credit: Kok Siong Chen and Khalid Shah.
Scientists developed a bifunctional therapeutic strategy by transforming living tumor cells into a therapeutic. Shah's team engineered living tumor cells using the gene-editing tool CRISPR-Cas9 and repurposed them to release tumor cell-killing agents. In addition, the engineered tumor cells were designed to express factors that would make them easy for the immune system to spot, tag, and remember, priming the immune system for a long-term anti-tumor response. The team tested their repurposed CRISPR-enhanced and reverse-engineered therapeutic tumor cells (ThTC) in different mice strains, including the one that bore bone marrow, liver, and thymus cells derived from humans, mimicking the human immune microenvironment. Shah's team also built a two-layered safety switch into the cancer cell, which, when activated, eradicates ThTCs if needed - Image Credit: Kok Siong Chen and Khalid Shah.
Continued...

Shah's team also built a two-layered safety switch into the cancer cell, which, when activated, eradicates ThTCs if needed. This dual-action cell therapy was safe, applicable, and efficacious in these models, suggesting a roadmap toward therapy. While further testing and development are needed, Shah's team chose this model and used human cells to smooth the path of translating their findings for patient settings.

"Throughout all of the work that we do in the Center, even when it is highly technical, we never lose sight of the patient," said Shah. "Our goal is to take an innovative but translatable approach to develop a therapeutic, cancer-killing vaccine that ultimately will have a lasting impact in medicine."

Shah and colleagues note that this therapeutic strategy applies to a wider range of solid tumors and that further investigations of its applications are warranted.

Disclosures:

Shah owns equity and is a member of the Board of Directors of AMASA Therapeutics, a company developing stem cell-based therapies for cancer.

Funding:

This work was supported by the National Institutes of Health (grant R01-NS121096).

Paper cited:

Chen KS et al. "Bifunctional cancer cell-based vaccine concomitantly drives direct tumor killing and antitumor immunity" Science Translational Medicine DOI: 10.1126/scitranslmed.abo4778

Attribution/Source(s):

This peer reviewed publication was selected for publishing by the editors of Disabled World due to its significant relevance to the disability community. Originally authored by Brigham and Women's Hospital, and published on 2023/01/06 (Edit Update: 2023/06/28), the content may have been edited for style, clarity, or brevity. For further details or clarifications, Brigham and Women's Hospital can be contacted at brighamandwomens.org. NOTE: Disabled World does not provide any warranties or endorsements related to this article.

Explore Related Topics

1 - - Researchers urge caution in gene editing early human embryos following findings that it could have unexpected and dangerous consequences.

2 - - Engineering living tumor cells using the gene-editing tool CRISPR-Cas9 and repurposing them to release tumor cell-killing agent.

3 - - The new technique, known as PASTE, could hold promise for treating diseases that are caused by defective genes with a large number of mutations, such as cystic fibrosis.

4 - - Studies reveal insufficient production of protein CAPRIN1 in the brain can lead to impairments, including ASD, ADHD, language disorders, and myasthenia.

5 - - New gene-editing technology could eliminate some inherited diseases but also change the course of human evolution.

Complete List of Related Information

Page Information, Citing and Disclaimer

Disabled World is a comprehensive online resource that provides information and news related to disabilities, assistive technologies, and accessibility issues. Founded in 2004 our website covers a wide range of topics, including disability rights, healthcare, education, employment, and independent living, with the goal of supporting the disability community and their families.

Cite This Page (APA): Brigham and Women's Hospital. (2023, January 6 - Last revised: 2023, June 28). Cancer Vaccine Kills and Prevents Brain Cancer. Disabled World. Retrieved October 7, 2024 from www.disabled-world.com/news/research/crispr/gene-editing.php

Permalink: <a href="https://www.disabled-world.com/news/research/crispr/gene-editing.php">Cancer Vaccine Kills and Prevents Brain Cancer</a>: Engineering living tumor cells using the gene-editing tool CRISPR-Cas9 and repurposing them to release tumor cell-killing agent.

Disabled World provides general information only. Materials presented are never meant to substitute for qualified medical care. Any 3rd party offering or advertising does not constitute an endorsement.